Rabbit Anti-IDH2 (Isocitrate Dehydrogenase 2) [MD68R]: RM0295, RM0295RTU7

Intended Use: For Research Use Only

Description: Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses that utilize either NAD or NADP+ as an electron acceptor. Five isocitrate dehydrogenases have been reported: three NAD dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP+ dependent isocitrate dehydrogenases, one of which is mitochondrial (IDH2) and the other predominantly cytosolic (IDH1). Each NADP+ dependent isozyme is a homodimer. IDH2, a 452 amino acid enzyme, is involved in the reduction of NADP+ to NADPH and maintains mitochondrial glutathione levels. It plays a role in intermediary metabolism and energy production. This protein may tightly associate or interact with the pyruvate dehydrogenase complex.

Specifications

	Description		Catalog No.	Size	
Package:					
Applications:		IHC, IP, WB			
Storage:		Store at 2°- 8°C			
Formulation:		Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN3)			
Localization:		Mitochondrion			
Immunogen:		Synthetic peptide of human IDH2 protein Val195			
Reactivity:		Human, mouse, rat			
Isotype:		IgG			
Source:		Rabbit			
Clone:		MD68R			
-					

Description	Catalog No.	Size
IDH2 (Isocitrate Dehydrogenase 2) Concentrated	RM0295	1 ml
IDH2 (Isocitrate Dehydrogenase 2) Prediluted	RM0295RTU7	7 ml

IHC Procedure*

Positive Control Tissue:	Liver
Concentrated Dilution:	25-100
Pretreatment:	Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes
	using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual
* Result should be confirmed by a	n established diagnostic procedure.



FFPE human colon adenocarcinoma stained with anti-IDH2 using DAB

References

- 1. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Filipp FV, et al. Pigment Cell Melanoma Res. May;25(3):375-83, 2012.
- 2. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Abbas S, et al. Blood. Sep 23;116(12):2122-6, 2010.
- 3. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Watanabe T, et al. Am J Pathol. Apr;174(4):1149-53, 2009.